BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated by Analysts at Wedbush

Investment analysts at Wedbush initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $15.00 price target on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 80.94% from the stock’s previous close.

Several other brokerages have also recently commented on BCRX. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Evercore ISI lifted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $15.43.

BioCryst Pharmaceuticals Trading Down 10.0 %

Shares of BCRX opened at $8.29 on Tuesday. The stock’s 50 day moving average is $8.03 and its two-hundred day moving average is $7.84. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The firm has a market capitalization of $1.72 billion, a PE ratio of -13.59 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $130.05 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 earnings per share. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after acquiring an additional 127,708 shares during the last quarter. Fisher Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the period. Caligan Partners LP raised its holdings in BioCryst Pharmaceuticals by 16.0% in the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock valued at $22,529,000 after acquiring an additional 412,347 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of BioCryst Pharmaceuticals by 14.6% during the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock worth $18,799,000 after purchasing an additional 318,800 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.